

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chen et al.

Serial No.:

10/046,681

Group Art Unit No.:

1614

Filed:

January 10, 2002

Examiner: Richard L. Raymond

For:

SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE

Docket No.:

A-733A

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant, by the undersigned attorney/agent, certifies that no information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Joseph W. Bulock

Attorney/Agent for Applicant(s)

Registration No.: 37,103 Phone: (805) 447-7966

Date: May 6, 2005

EXPRESS MAIL CERTIFICATE

EL732819232US

Date of Deposit:

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew

Printed Name

Please send all future correspondence to:

U.S. Patent Operations/JWB Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799 Modified Form PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. Serial No.

A-733A 10/046.681

Applicant

Chen et al.

Filing Date

Group

January 10, 2002

1614

January 10, 2002							014	
MAY 0. S	2005							
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
ENTE TRAI	1 6	6,635,657 B1	21 Oct 2003	Beight et al.				
	A7	6,605,626 B2	12 Aug 2003	Beight et al.				
	A8	6,417,200 B1	9 July 2002	Beight et al.				
	A9	6,372,759 B1	16 Apr 2002	Beight et al.				
	A10	6,313,122 B1	6 Nov 2001	Beight et al.				
	A11	6,313,151 B1	6 Nov 2001	Beight et al.				
	A12	6,610,704 B1	26 Aug 2003	Beight et al.				
	A13	2003/0069250 A1	10 Apr 2003	Zhu et al.				
	A14	2004/0254185 A1	16 Dec 2004	Ernst et al.				
	A15	6,051,713	18 Apr 2000	Teng et al.				
	A16	4,816,485	28 Mar 1989	Satzinger et al.				
	A17	4,857,662	15 Aug 1989	Satzinger et al.				
	A18	6,156,766	5 Dec 2000	Arita et al.		<u>.</u>		
	A19	4,321,371	23 Mar 1982	Parg et al.				
	A20	2004/0102441 A1	27 May 2004	Krueger et al.				
_	A21	5,559,135	24 Sep 1996	Ashton et al.				
	A22	6,593,352 B2	15 July 2003	Weichert et al.			·	
	A23	6,660,755 B2	9 Dec 2003	Song et al.				
	A24	6,448,290 B1	10 Sep 2002	Ohuchida et al.				
	A25	3,822,277	2 July 1974	Claude Dufour				
	A26	5,770,613	23 Jun 1998	Gaeta et al.				
	A27	5,571,912	5 Nov 1996	Grozinger et al.				
	A28	3,406,168	15 Oct 1968	Gunther Schmidt				
	A29	6,008,234	28 Dec 1999	Kochanny et al.				
	A30	2004/0063775 A1	1 Apr 2004	Momose et al.				

EXAMINER:	Date Considered:
EXAMINER:	Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	2	Of	- 0
OHEEL		0.	

									sneet 2	. Of	2
Modified Form PTO-1449				A	tty. Docket No.			Serial	No.		
				_				10/046.	681		
LIST OF REFERENCES CITED BY APPLICANT				^	Applicant Chen et al.						
(Use several sheets if necessary)			F	iling Date	Onon ot al.		Group				
					January 10, 200	2	1614				
MAY 0 6 2005											
EXAMINER'S INITIALS	3	DOCUMENT NUMBER	DATE	NAME			CLA	SS	SUB- CLASS	FILING APPRO	DATE IF PRIATE
& TRA	A31	2003/0195192 A1	16 Oct 2003		Haviv et al.						
	A32	2003/0195195 A1	16 Oct 2003	03 Haviv et al.							
	A33	2005/0032816 A1	10 Feb 2005	Ernst et al.							
	A34	6,794,397 B2	21 Sep 2004	Cai et al.							
	A35	2005/0054654 A1	10 Mar 2005	5 Huth et al.							
	A36	6,271,237 B1	7 Aug 2001	2001 Galemmo, Jr. et al.					<u></u>		
	·		FOREIGN PAT	ENT D	OCUME	NTS					
EXAMINER'S INITIALS				co	UNTRY	Cl	ASS	SUB- CLASS	TRANSI YES	LATION NO	
	B27	WO 03/068235 A1	21 Aug 2003	PCT		PCT					
	B28	WO 03/068232 A1	21 Aug 2003	003		СТ					
·	B29	EP 0 429 987 A2	5 Jun 1991	Europe							
	B30	EP 0 393 529 B1	30 Jun 1993	Europe							
	B31	EP 0 410 148 A1	30 Jan 1991	Europe							
	B32	EP 0 393 529 A1	24 Oct 1990		Europe						
EXAMINER'S INITIALS											
4	l ^^	Droudfoot at al. "Noval	Mon-nucleocide li	nhihita	re or HIV	.1 Dovorco Tran	ecrinta	C 2	Dinyride	リク スーカビ	ン' マ'_ 「

C9 Proudfoot et al., "Novel Non-nucleoside Inhibitors or HIV-1 Reverse Transcriptase. 3. Dipyrido[2,3-b:2',3'-e]diazepinones", J. Med. Chem., 38:1406-1410 (1995). C10 Smrckova-Voltrova et al., "Structure and Properties of Quaternized 2- and 4-aminonicotinamides", Collect. Czech. Chem. Commun., 50:1009-1015 (1995). C11 Samvelyan et al., "Discussion of Some New Amino Acid Derivatives of Nicotinic Acid and Their Antisoporific Properties", Farmakologiia I Toksikologiia, 49(3):35-37 (1986). C12 Hargrave et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones", J. Med. Chem., 34:2231-2241 (1991). C13 Adams et al., "Discovery and Development of a Non-nucleoside Reverse Transcriptase Inhibitor", Royal Society of Chemistry, Recent Advances in the Chemistry of Anti-infective Agents, 19:282-296 (1993).

,	
EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation	n if not in conformance and not considered. Include copy of this form with next

communication to applicant.